Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Clinical Research›Proportional Hazards Models
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Proportional Hazards Models

Clinical Research · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (834 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Proportional Hazards Model; Hazards Model, Proportional; Hazards Models, Proportional; Model, Proportional Hazards; Proportional Hazard Model; Hazard Model, Proportional; Hazard Models, Proportional; Model, Proportional Hazard.

Where it fits in the MeSH classification

Broader topics
Models, Statistical; Probability; Regression Analysis; Survival Analysis

Research landscape

PubMed indexes 102,241 records tagged with the MeSH heading “Proportional Hazards Models” (counts retrieved 2026-10-29). 23,154 of them (22.6%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 54,476 records.

Reviews account for 2,696 records (2.6%) and meta-analyses for 1,855. Randomized controlled trials number 5,294 (5.2%) as a share of all records on the topic.

PubMed records by publication periodthrough 1999: 4,547 records; 2000-2009: 20,064 records; 2010-2019: 54,476 records; 2020 onward: 23,154 records4,547through 199920,0642000-200954,4762010-201923,1542020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19994,547
2000-200920,064
2010-201954,476
2020 onward23,154
Share of records by publication typeReviews: 2.6 percent; Meta-analyses: 1.8 percent; Randomized controlled trials: 5.2 percentReviews2.6% (2,696)Meta-analyses1.8% (1,855)Randomized controlled trials5.2% (5,294)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 102,241 PubMed records
TypeRecordsShare
Reviews2,6962.6%
Meta-analyses1,8551.8%
Randomized controlled trials5,2945.2%

Method: PubMed query "Proportional Hazards Models"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in clinical research

Research methods determine how much a result can be trusted. Randomized trials guard against confounding, systematic reviews and meta-analyses combine many studies, and observational designs are valuable but can show only association. Reporting standards, trial registration and pre-specified outcomes reduce bias. When reading about a method, ask what problem it is designed to solve and which problems it does not solve.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network
Katzman JL, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y
2018Research article
Design not recorded in structured metadata
1,090cc by
PMID 29482517 · DOI · PMC5828433
Adequate sample size for developing prediction models is not simply related to events per variable
Ogundimu EO, Altman DG, Collins GS
2016Research article
Design not recorded in structured metadata
417cc by
PMID 26964707 · DOI · PMC5045274
Cox-nnet: An artificial neural network method for prognosis prediction of high-throughput omics data
Ching T, Zhu X, Garmire LX
2018Research article
Design not recorded in structured metadata
243cc by
PMID 29634719 · DOI · PMC5909924
Source-specific nitrate intake and all-cause mortality in the Danish Diet, Cancer, and Health Study
Bondonno NP, Pokharel P, Bondonno CP, Erichsen DW, Zhong L, Schullehner J, et al.
2024Research article
Design not recorded in structured metadata
19cc by
PMID 38802612 · DOI · PMC11410901

DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network [1]

Research article Katzman JL, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y · · 2018 · cited 1,090 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundMedical practitioners use survival models to explore and understand the relationships between patients' covariates (e.
Closing excerpt
ConclusionsThe predictive and modeling capabilities of DeepSurv will enable medical researchers to use deep neural networks as a tool in their exploration, understanding, and prediction of the effects of a patient's characteristics on their risk of failure.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (248 words)

BackgroundMedical practitioners use survival models to explore and understand the relationships between patients' covariates (e.g. clinical and genetic features) and the effectiveness of various treatment options. Standard survival models like the linear Cox proportional hazards model require extensive feature engineering or prior medical knowledge to model treatment interaction at an individual level. While nonlinear survival methods, such as neural networks and survival forests, can inherently model these high-level interaction terms, they have yet to be shown as effective treatment recommender systems.MethodsWe introduce DeepSurv, a Cox proportional hazards deep neural network and state-of-the-art survival method for modeling interactions between a patient's covariates and treatment effectiveness in order to provide personalized treatment recommendations.ResultsWe perform a number of experiments training DeepSurv on simulated and real survival data. We demonstrate that DeepSurv performs as well as or better than other state-of-the-art survival models and validate that DeepSurv successfully models increasingly complex relationships between a patient's covariates and their risk of failure. We then show how DeepSurv models the relationship between a patient's features and effectiveness of different treatment options to show how DeepSurv can be used to provide individual treatment recommendations. Finally, we train DeepSurv on real clinical studies to demonstrate how it's personalized treatment recommendations would increase the survival time of a set of patients.ConclusionsThe predictive and modeling capabilities of DeepSurv will enable medical researchers to use deep neural networks as a tool in their exploration, understanding, and prediction of the effects of a patient's characteristics on their risk of failure.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29482517 · DOI · PMC5828433

Adequate sample size for developing prediction models is not simply related to events per variable [2]

Research article Ogundimu EO, Altman DG, Collins GS · · 2016 · cited 417 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
ObjectivesThe choice of an adequate sample size for a Cox regression analysis is generally based on the rule of thumb derived from simulation studies of a minimum of 10 events per variable (EPV).
Closing excerpt
ConclusionHigher EPV is needed when low-prevalence predictors are present in a model to eliminate bias in regression coefficients and improve predictive accuracy.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (186 words)

ObjectivesThe choice of an adequate sample size for a Cox regression analysis is generally based on the rule of thumb derived from simulation studies of a minimum of 10 events per variable (EPV). One simulation study suggested scenarios in which the 10 EPV rule can be relaxed. The effect of a range of binary predictors with varying prevalence, reflecting clinical practice, has not yet been fully investigated.Study design and settingWe conducted an extended resampling study using a large general-practice data set, comprising over 2 million anonymized patient records, to examine the EPV requirements for prediction models with low-prevalence binary predictors developed using Cox regression. The performance of the models was then evaluated using an independent external validation data set. We investigated both fully specified models and models derived using variable selection.ResultsOur results indicated that an EPV rule of thumb should be data driven and that EPV ≥ 20 ​ generally eliminates bias in regression coefficients when many low-prevalence predictors are included in a Cox model.ConclusionHigher EPV is needed when low-prevalence predictors are present in a model to eliminate bias in regression coefficients and improve predictive accuracy.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 26964707 · DOI · PMC5045274

Cox-nnet: An artificial neural network method for prognosis prediction of high-throughput omics data [3]

Research article Ching T, Zhu X, Garmire LX · · 2018 · cited 243 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Artificial neural networks (ANN) are computing architectures with many interconnections of simple neural-inspired computing elements, and have been applied to biomedical fields such as imaging analysis and diagnosis.
Closing excerpt
com/lanagarmire/cox-nnet.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (138 words)

Artificial neural networks (ANN) are computing architectures with many interconnections of simple neural-inspired computing elements, and have been applied to biomedical fields such as imaging analysis and diagnosis. We have developed a new ANN framework called Cox-nnet to predict patient prognosis from high throughput transcriptomics data. In 10 TCGA RNA-Seq data sets, Cox-nnet achieves the same or better predictive accuracy compared to other methods, including Cox-proportional hazards regression (with LASSO, ridge, and mimimax concave penalty), Random Forests Survival and CoxBoost. Cox-nnet also reveals richer biological information, at both the pathway and gene levels. The outputs from the hidden layer node provide an alternative approach for survival-sensitive dimension reduction. In summary, we have developed a new method for accurate and efficient prognosis prediction on high throughput data, with functional biological insights. The source code is freely available at https://github.com/lanagarmire/cox-nnet.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29634719 · DOI · PMC5909924

Source-specific nitrate intake and all-cause mortality in the Danish Diet, Cancer, and Health Study [4]

Research article Bondonno NP, Pokharel P, Bondonno CP, Erichsen DW, Zhong L, Schullehner J, et al. · · 2024 · cited 19 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
IntroductionNitrate and nitrite are naturally occurring in both plant- and animal-sourced foods, are used as additives in the processing of meat, and are found in water.
Closing excerpt
ConclusionNitrate/nitrite from plant sources are inversely associated while those from naturally occurring animal-sources, additive-permitted meat sources, and tap water-sources are positively associated with mortality.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (262 words)

IntroductionNitrate and nitrite are naturally occurring in both plant- and animal-sourced foods, are used as additives in the processing of meat, and are found in water. There is growing evidence that they exhibit a spectrum of health effects, depending on the dietary source. The aim of the study was to examine source-dependent associations between dietary intakes of nitrate/nitrite and both all-cause and cause-specific mortality.MethodsIn 52,247 participants of the Danish Diet, Cancer and Health Study, associations between source-dependent nitrate and nitrite intakes--calculated using comprehensive food composition and national drinking water quality monitoring databases--and all-cause, cardiovascular disease (CVD)-related, and cancer-related mortality over 27 years were examined using restricted cubic splines within Cox proportional hazards models adjusting for demographic, lifestyle, and dietary confounders. Analyses were stratified by factors hypothesised to influence the formation of carcinogenic N-nitroso compounds (namely, smoking and dietary intakes of vitamin C, vitamin E, folate, and polyphenols).ResultsPlant-sourced nitrate intake was inversely associated with all-cause mortality [HRQ5vsQ1: 0.83 (0.80, 0.87)] while higher risks of all-cause mortality were seen for higher intakes of naturally occurring animal-sourced nitrate [1.09 (1.04, 1.14)], additive permitted meat-sourced nitrate [1.19 (1.14, 1.25)], and tap water-sourced nitrate [1.19 (1.14, 1.25)]. Similar source-dependent associations were seen for nitrite and for CVD-related and cancer-related mortality except that naturally occurring animal-sourced nitrate and tap water-sourced nitrate were not associated with cancer-related mortality and additive permitted meat-sourced nitrate was not associated with CVD-related mortality. No clear patterns emerged in stratified analyses.ConclusionNitrate/nitrite from plant sources are inversely associated while those from naturally occurring animal-sources, additive-permitted meat sources, and tap water-sources are positively associated with mortality.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38802612 · DOI · PMC11410901

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 [5]
    Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. · Neurology · 2007 · cited 1,629 times (Europe PMC)
  • Research article How common are the "common" neurologic disorders? [6]
    Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R · Neurology · 2007 · cited 948 times (Europe PMC)
  • Research article Time-dependent covariates in the Cox proportional-hazards regression model [7]
    Fisher LD, Lin DY · Annu Rev Public Health · 1999 · cited 690 times (Europe PMC)
  • Research article Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis [8]
    Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al. · JAMA · 2016 · cited 576 times (Europe PMC)
  • Research article Hazard ratio in clinical trials [9]
    Spruance SL, Reid JE, Grace M, Samore M · Antimicrob Agents Chemother · 2004 · cited 337 times (Europe PMC)
  • Research article Survival analysis and regression models [10]
    George B, Seals S, Aban I · J Nucl Cardiol · 2014 · cited 283 times (Europe PMC)

References

  1. Katzman JL, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y. DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. . 2018. PMID 29482517 · DOI · PMC5828433
  2. Ogundimu EO, Altman DG, Collins GS. Adequate sample size for developing prediction models is not simply related to events per variable. . 2016. PMID 26964707 · DOI · PMC5045274
  3. Ching T, Zhu X, Garmire LX. Cox-nnet: An artificial neural network method for prognosis prediction of high-throughput omics data. . 2018. PMID 29634719 · DOI · PMC5909924
  4. Bondonno NP, Pokharel P, Bondonno CP, Erichsen DW, Zhong L, Schullehner J, et al.. Source-specific nitrate intake and all-cause mortality in the Danish Diet, Cancer, and Health Study. . 2024. PMID 38802612 · DOI · PMC11410901
  5. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al.. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007. PMID 17082464 · DOI
  6. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders?. Neurology. 2007. PMID 17261678 · DOI
  7. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999. PMID 10352854 · DOI
  8. Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al.. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA. 2016. PMID 26757465 · DOI · PMC4752167
  9. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004. PMID 15273082 · DOI · PMC478551
  10. George B, Seals S, Aban I. Survival analysis and regression models. J Nucl Cardiol. 2014. PMID 24810431 · DOI · PMC4111957

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Linear ModelsClinical Research
  • Logistic ModelsClinical Research
  • NomogramsClinical Research
  • Latent Class AnalysisClinical Research
  • Regression AnalysisClinical Research
  • Cardiometabolic Risk FactorsClinical Research

All 98 articles in Clinical Research →

At a glance

102,241
PubMed records on this heading
23%
published since 2020
2,696
review articles
5,294
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Linear ModelsClinical Research
  • Logistic ModelsClinical Research
  • NomogramsClinical Research
  • Latent Class AnalysisClinical Research
  • Regression AnalysisClinical Research

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support